Dose-specific effects of denosumab on serum calcium levels in patients with osteoporosis and various renal functions

Patients with osteoporosis and advanced chronic kidney disease (CKD) are at increased risk for hypocalcemia when initiating denosumab. It remains unclear if subsequent doses of denosumab pose similar hypocalcemia risk as the initial dose does.